Browse HLA-DMB

Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Late endosome membrane Single-pass type I membrane protein Lysosome membrane Single-pass type I membrane protein Note=Localizes to late endocytic compartment. Associates with lysosome membranes.
Domain PF07654 Immunoglobulin C1-set domain
PF00969 Class II histocompatibility antigen
Function

Plays a critical role in catalyzing the release of class II-associated invariant chain peptide (CLIP) from newly synthesized MHC class II molecules and freeing the peptide binding site for acquisition of antigenic peptides. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO.

> Gene Ontology
 
Biological Process GO:0002263 cell activation involved in immune response
GO:0002285 lymphocyte activation involved in immune response
GO:0002286 T cell activation involved in immune response
GO:0002291 T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:0002366 leukocyte activation involved in immune response
GO:0002396 MHC protein complex assembly
GO:0002399 MHC class II protein complex assembly
GO:0002478 antigen processing and presentation of exogenous peptide antigen
GO:0002495 antigen processing and presentation of peptide antigen via MHC class II
GO:0002501 peptide antigen assembly with MHC protein complex
GO:0002503 peptide antigen assembly with MHC class II protein complex
GO:0002504 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II
GO:0002694 regulation of leukocyte activation
GO:0002696 positive regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0007159 leukocyte cell-cell adhesion
GO:0019882 antigen processing and presentation
GO:0019884 antigen processing and presentation of exogenous antigen
GO:0019886 antigen processing and presentation of exogenous peptide antigen via MHC class II
GO:0022407 regulation of cell-cell adhesion
GO:0022409 positive regulation of cell-cell adhesion
GO:0032943 mononuclear cell proliferation
GO:0032944 regulation of mononuclear cell proliferation
GO:0032946 positive regulation of mononuclear cell proliferation
GO:0042098 T cell proliferation
GO:0042102 positive regulation of T cell proliferation
GO:0042110 T cell activation
GO:0042129 regulation of T cell proliferation
GO:0045785 positive regulation of cell adhesion
GO:0046651 lymphocyte proliferation
GO:0048002 antigen processing and presentation of peptide antigen
GO:0050670 regulation of lymphocyte proliferation
GO:0050671 positive regulation of lymphocyte proliferation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050867 positive regulation of cell activation
GO:0050870 positive regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051251 positive regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0070661 leukocyte proliferation
GO:0070663 regulation of leukocyte proliferation
GO:0070665 positive regulation of leukocyte proliferation
GO:0071593 lymphocyte aggregation
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903039 positive regulation of leukocyte cell-cell adhesion
GO:2001188 regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
GO:2001190 positive regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell
Molecular Function GO:0003823 antigen binding
GO:0023023 MHC protein complex binding
GO:0023026 MHC class II protein complex binding
Cellular Component GO:0005765 lysosomal membrane
GO:0005770 late endosome
GO:0010008 endosome membrane
GO:0031902 late endosome membrane
GO:0042611 MHC protein complex
GO:0042613 MHC class II protein complex
GO:0044440 endosomal part
GO:0098852 lytic vacuole membrane
> KEGG and Reactome Pathway
 
KEGG hsa04145 Phagosome
hsa04514 Cell adhesion molecules (CAMs)
hsa04612 Antigen processing and presentation
hsa04640 Hematopoietic cell lineage
hsa04672 Intestinal immune network for IgA production
Reactome R-HSA-1280218: Adaptive Immune System
R-HSA-168256: Immune System
R-HSA-2132295: MHC class II antigen presentation
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HLA-DMB and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HLA-DMB in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HLA-DMB in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0040.991
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.1440.836
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0970.866
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.8080.127
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.440.779
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 471.2840.562
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.3460.523
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.7230.679
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1670.936
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.880.706
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8290.823
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1220.507
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HLA-DMB in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HLA-DMB. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HLA-DMB. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HLA-DMB.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HLA-DMB. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HLA-DMB expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HLA-DMB and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHLA-DMB
Namemajor histocompatibility complex, class II, DM beta
Aliases D6S221E; RING7; MHC class II HLA-DMB; MHC class II antigen DMB; MHC class II antigen HLA-DM beta chain; clas ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HLA-DMB collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.